[go: up one dir, main page]

WO1992000074A3 - Derives de pyridopyrazine utilises dans le traitement contre la consommation et la dependance de substances toxiques - Google Patents

Derives de pyridopyrazine utilises dans le traitement contre la consommation et la dependance de substances toxiques Download PDF

Info

Publication number
WO1992000074A3
WO1992000074A3 PCT/US1991/003749 US9103749W WO9200074A3 WO 1992000074 A3 WO1992000074 A3 WO 1992000074A3 US 9103749 W US9103749 W US 9103749W WO 9200074 A3 WO9200074 A3 WO 9200074A3
Authority
WO
WIPO (PCT)
Prior art keywords
addiction
substance abuse
treating substance
pyridopyrazine derivatives
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1991/003749
Other languages
English (en)
Other versions
WO1992000074A2 (fr
Inventor
Gene Michael Bright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Priority to AU79094/91A priority Critical patent/AU651977B2/en
Priority to DE69106516T priority patent/DE69106516T2/de
Priority to EP91910566A priority patent/EP0536173B1/fr
Priority to JP91510300A priority patent/JPH05507274A/ja
Publication of WO1992000074A2 publication Critical patent/WO1992000074A2/fr
Publication of WO1992000074A3 publication Critical patent/WO1992000074A3/fr
Priority to KR1019920703374A priority patent/KR930701171A/ko
Anticipated expiration legal-status Critical
Priority to US08/377,874 priority patent/US5616585A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Des dérivées de pyrido[1,2-a]pyrazine racémiques ou optiquement actifs de formule (I), dans laquelle Y répresente N ou CH et Y répresente un radical parmi certains radicaux pyrazolo, triazolo, tétrazolo ou imido cycliques sont utiles pour le traitement contre la consommation et/ou la dépendance de substances telles que les narcotiques, l'alcool et la nicotine.
PCT/US1991/003749 1990-06-29 1991-05-28 Derives de pyridopyrazine utilises dans le traitement contre la consommation et la dependance de substances toxiques Ceased WO1992000074A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU79094/91A AU651977B2 (en) 1990-06-29 1991-05-28 Pyridopyrazine derivatives for treating substance abuse and addiction
DE69106516T DE69106516T2 (de) 1990-06-29 1991-05-28 Pyridopyrazinderivate zur behandlung von drogenmissbrauch und -sucht.
EP91910566A EP0536173B1 (fr) 1990-06-29 1991-05-28 Derives de pyridopyrazine utilises dans le traitement contre la consommation et la dependance de substances toxiques
JP91510300A JPH05507274A (ja) 1990-06-29 1991-05-28 薬物の乱用及び嗜癖を治療するためのピリドピラジン誘導体
KR1019920703374A KR930701171A (ko) 1990-06-29 1992-12-28 물질의 남용 및 중독 치료용 피리도피라진 유도체
US08/377,874 US5616585A (en) 1990-06-29 1995-01-25 Pyridopyrazine derivatives for treating alcohol and nicotine abuse and addiction

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
USPCT/US90/03708 1990-06-29
PCT/US1990/003708 WO1992000075A1 (fr) 1990-06-29 1990-06-29 Derives de pyridopyrazine utilises dans le traitement de l'abus et de la dependance de substances

Publications (2)

Publication Number Publication Date
WO1992000074A2 WO1992000074A2 (fr) 1992-01-09
WO1992000074A3 true WO1992000074A3 (fr) 1992-03-05

Family

ID=22220931

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1990/003708 Ceased WO1992000075A1 (fr) 1990-06-29 1990-06-29 Derives de pyridopyrazine utilises dans le traitement de l'abus et de la dependance de substances
PCT/US1991/003749 Ceased WO1992000074A2 (fr) 1990-06-29 1991-05-28 Derives de pyridopyrazine utilises dans le traitement contre la consommation et la dependance de substances toxiques

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US1990/003708 Ceased WO1992000075A1 (fr) 1990-06-29 1990-06-29 Derives de pyridopyrazine utilises dans le traitement de l'abus et de la dependance de substances

Country Status (17)

Country Link
US (1) US5616585A (fr)
EP (1) EP0536173B1 (fr)
JP (1) JPH05507274A (fr)
KR (1) KR930701171A (fr)
AT (1) ATE116545T1 (fr)
AU (1) AU651977B2 (fr)
CA (1) CA2086335C (fr)
DE (1) DE69106516T2 (fr)
DK (1) DK0536173T3 (fr)
ES (1) ES2066447T3 (fr)
HU (1) HUT62797A (fr)
IE (1) IE64467B1 (fr)
IL (1) IL98588A (fr)
MY (1) MY106553A (fr)
NZ (1) NZ238750A (fr)
WO (2) WO1992000075A1 (fr)
ZA (1) ZA915012B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6231833B1 (en) 1999-08-05 2001-05-15 Pfizer Inc 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors
HN1999000146A (es) * 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
EP1177792A3 (fr) * 2000-07-27 2002-10-23 Pfizer Products Inc. Ligands dopamine d4 destines au traitement des troubles associees a la cherche de la nouveaute
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
CN107406445B (zh) 2015-02-03 2019-12-24 辉瑞公司 新颖环丙苯并呋喃基吡啶并吡嗪二酮类

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0285008A2 (fr) * 1987-03-25 1988-10-05 Bristol-Myers Squibb Company Utilisation de buspirone pour la préparation d'une composition pharmaceutique pour le traitement de l'abus d'alcool
EP0303951A2 (fr) * 1987-08-21 1989-02-22 Troponwerke GmbH & Co. KG Dérivés de 2-pyrimidinyl-1-pipérazine pour le traitement de l'alcoolisme
EP0314984A2 (fr) * 1987-10-31 1989-05-10 Troponwerke GmbH & Co. KG Application des dérivés de la 2-pyrimidinyl-1-pipérazine
EP0356997A2 (fr) * 1988-08-30 1990-03-07 Bristol-Myers Squibb Company Utilisation de buspirone pour préparer de compositions pharmaceutiques pour le traitement de l'asservissement aux drogues
EP0380217A1 (fr) * 1989-01-23 1990-08-01 Pfizer Inc. Agents bis-aza-bicycliques anxiolytiques et antidépresseurs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK144213C (da) * 1979-06-20 1982-06-21 H B Nielsen Hylster til garnspole

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0285008A2 (fr) * 1987-03-25 1988-10-05 Bristol-Myers Squibb Company Utilisation de buspirone pour la préparation d'une composition pharmaceutique pour le traitement de l'abus d'alcool
EP0303951A2 (fr) * 1987-08-21 1989-02-22 Troponwerke GmbH & Co. KG Dérivés de 2-pyrimidinyl-1-pipérazine pour le traitement de l'alcoolisme
EP0314984A2 (fr) * 1987-10-31 1989-05-10 Troponwerke GmbH & Co. KG Application des dérivés de la 2-pyrimidinyl-1-pipérazine
EP0356997A2 (fr) * 1988-08-30 1990-03-07 Bristol-Myers Squibb Company Utilisation de buspirone pour préparer de compositions pharmaceutiques pour le traitement de l'asservissement aux drogues
EP0380217A1 (fr) * 1989-01-23 1990-08-01 Pfizer Inc. Agents bis-aza-bicycliques anxiolytiques et antidépresseurs

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Arch. Gen. Psychiatry, volume 46, no. 3, March 1989, F. Gawin et al.: "Buspirone reduces smoking", pages 288-289, see the whole article *
Clinical Pharmacy, volume 8, October 1989, American Soc. of Hospital Pharmacists Inc., C.L. Nunn-Thompson et al.: "Pharmacotherapy for smoking cessation", pages 710-720, see the whole article, especially page 717 *
Drug and Alcohol Dependence, volume 21, May 1988, Elsevier Scientific Publ. , Ireland Ltd, K. Optiz et al.: "Volitional oral intake of nicotine in tupaias: drug-induced alterations", pages 99-105, see the whole article *
International Journal of Obesity, volume 14, March 1990, MacMillan Press Ltd, H. Tamai et al.: "The clinical efficacy of a 5-HT1A agonist, SM-3997, in the treatment of bulimia", pages 289-292, see the whole article *
Journal of Clinical Psychopharmacology, volume 7, no. 1, February 1987, Williams & Wilkins Co., M. Lader et al.: "A comparison of buspirone and placebo in relieving benzodiazepine withdrawal symptoms", pages 11-15, see the whole article *

Also Published As

Publication number Publication date
HU9204138D0 (en) 1993-04-28
MY106553A (en) 1995-06-30
IL98588A0 (en) 1992-07-15
IL98588A (en) 1995-06-29
ATE116545T1 (de) 1995-01-15
IE912259A1 (en) 1992-01-01
AU651977B2 (en) 1994-08-11
EP0536173A1 (fr) 1993-04-14
WO1992000075A1 (fr) 1992-01-09
KR930701171A (ko) 1993-06-11
HUT62797A (en) 1993-06-28
ES2066447T3 (es) 1995-03-01
NZ238750A (en) 1999-09-29
US5616585A (en) 1997-04-01
ZA915012B (en) 1993-02-24
AU7909491A (en) 1992-01-23
EP0536173B1 (fr) 1995-01-04
DK0536173T3 (da) 1995-05-01
CA2086335C (fr) 1996-01-02
CA2086335A1 (fr) 1991-12-30
DE69106516D1 (de) 1995-02-16
DE69106516T2 (de) 1995-05-11
WO1992000074A2 (fr) 1992-01-09
JPH05507274A (ja) 1993-10-21
IE64467B1 (en) 1995-08-09

Similar Documents

Publication Publication Date Title
HUT61311A (en) Process for producing /1,2,4/triazolo/1,5-a//1,3,5/-traizine and pyrazolo/2,3-a//1,3,5/-triazine derivatives and pharmaceutical compositions comprising same as active ingredient
AU7668781A (en) Imidazo(1,2-a)pyridine derivatives
FR2607813B1 (fr) Alkylamino-8 imidazo (1,2-a) pyrazines et derives, leur preparation et leur application en therapeutique
HU9302063D0 (en) Method for producing optically active 5h-pyrrolo(3,4-b)pyrazine derivatives and one for producing pharmaceutical preparatives containing them as active agent
HUT74679A (en) K-252a indolocarbazole alkaloid derivatives which enhance neurotrophin-induced activity
KR880001641A (ko) 니트로푸란 유도체, 그의 제법 및 치료에의 응용
DK531089D0 (da) Bicycliske imidazolforbindelser til anvendelse ved behandling af hyperaldosteronisme
DE68925270D1 (de) Pyrrolo[3,2-e]pyrazolo[1,5-a]pyrimidinderivate und diese enthaltende Arzneimittel
BG98124A (bg) Нови активни пирило-(2,3-бета) пиридин производни
WO1992000074A3 (fr) Derives de pyridopyrazine utilises dans le traitement contre la consommation et la dependance de substances toxiques
FR2719843B1 (fr) Dérivés de 5,6-dihydro-4h-imidazo [2',1':2,3] imidazo-[4,5,1-ij] quinoléine et de 4,5-dihydroimidazo [1,2-a] pyrrolo-[1,2,3-cd] benzimidazole, leur préparation et leur application en thérapeutique.
EP0436831A3 (en) Imidazo(1,2-a)pyridinylalkyl compounds for treatment of neurotoxic injury
RU95105159A (ru) 3-карбоксальдегидные производные хинолина и нафтиридина, антибактериальная композиция, способ лечения
ES2062351T3 (es) Derivados de triazolo (4,5-c) piridina anticonvulsivos.
DE59107405D1 (de) Ein Imidazobenzodiazepin zur Behandlung von Schlafstörungen
PT84275A (en) Process for the preparation of tetracyclic quinazolinones

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA HU JP KR US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA HU JP KR US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1991910566

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2086335

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1991910566

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1991910566

Country of ref document: EP